Excaliard Pharmaceuticals Inc reports improved data from Phase 2 clinical trial of EXC 001 for skin scarring.
M2 EQUITYBITES-4 August 2010-Excaliard Pharmaceuticals Inc reports improved data from Phase 2 clinical trial of EXC 001 for skin scarring(C)2010 M2 COMMUNICATIONS http://www.m2.com
Biotechnology company Excaliard Pharmaceuticals Inc said on Tuesday that the company has received positive results from its Phase 2 clinical trial of EXC 001, a new chemical entity for reducing fibrosis, in the randomised, double-blind multicentre study conducted in the US.
According to the company, the results showed that EXC 001 treatment significantly reduced scar severity in subjects undergoing an elective abdominoplasty compared to placebo.
The company claimed that the final analysis for this study will be conducted 24 weeks after surgery and the data will be available in the second half of 2010.
EXC 001 was reportedly co-discovered by Isis Pharmaceuticals Inc (Nasdaq:ISIS) and Excaliard and licensed to Excaliard Pharmaceuticals.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Aug 4, 2010|
|Previous Article:||Watson Pharmaceuticals names Robert Stewart as executive vice president, global operations.|
|Next Article:||RBC Life Sciences posts 16% raise in second quarter sales.|